Next Phase Newsletter

A USA-based firm with multiple billion dollars of assets under management, invests from its latest fund that closed in 2023. The firm makes investments in the form of equity (preferred stock) and is an activist investor; the firm prefers to lead investments, take a board seat at its portfolio companies and be actively involved in company management. The firm plans to make 6-8 new investments in life science companies per year. 

The firm invests in biopharmaceuticals and typically makes initial investments of $5-15m, with the potential for a total investment of $15-40m.  The fund invests in companies based globally, with a focus on North America or Europe. 
 
The firm invests exclusively in therapeutics.  The firm will consider opportunities in any indication area but generally does not invest in cardiovascular disorders, diabetes, or other acute chronic care fields. The firm is particularly interested in oncology, specialty drugs, orphan drugs, and other areas where there is a defined clinical path to move the asset toward approval.  While the firm usually only invests in assets in Phase II or Phase III, the firm may consider earlier opportunities in oncology, ophthalmology, dermatology, and infectious diseases.  The firm is open to working with companies in any area of therapeutic technology but is particularly interested in biologics, and has also invested in biosimilars.   

In addition to investing in existing companies, this fund also invests in spinouts (typically from pharma companies); for spinouts, Phase II or earlier products are more likely to be considered as the pharma companies are typically able to provide a significant amount of trial data. 
 
The firm prefers to back management teams that have worked together before; it’s preferred that the team have experience of launching products, and have worked in both small and large biotech companies.  While experience is an important consideration, the firm has also worked with first-time CEOs.  For investments other than spinouts, the firm prefers to work with privately-held companies but also has past experience of PIPEs. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
 

A global leading IVD (in vitro diagnostics) company has its main business in hematology, hematosis, urinalysis, immunochemistry, and clinical chemistry with over $3B in net sales. Regarding their Digital Healthcare Section, the office is in the Bay Area in Northern California and is scouting for opportunities in North America, from startups to co-development and co-investment, to compliment the firm’s internal product portfolio (e.g. blood biomarkers) and expand their digital healthcare business. Equity investments are made on a case-by-case basis, but when applicable, the corporation is looking for companies generally in Series A and B rounds with typical check size ranging from $1-10M USD. The corporation will also provide commercialization support in Japan and overseas markets. 
 
The firm is currently looking for companies that strategically align with their main business as well as (1) finding digital technologies that can assist with patient stratification and early risk identification to increase testing volume on the firm’s IVD tests (early identification), (2) digital therapeutics that can increase the value of diagnostics, and (3) enter new areas of homecare by utilizing blood biomarker assets and digital solutions. Subsectors include, but are not limited to, digital health, home care, digital therapeutics, digital biomarkers, and clinical decision support. Companies should typically be conducting clinical trials however, pre-clinical stages may be of considered. Interested indications are CNS diseases, cardiovascular diseases, lifestyle diseases (e.g. hypertension), mental health, and chronic kidney diseases. 
 
The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm with USA offices is currently seeking new investments in the healthcare IT and tech enabled healthcare services sectors. The firm has raised 5 healthcare funds over the last 15 years and is currently deploying out of a late-seed stage focused as well as a Series A focused fund. The firm looks to invest in companies at venture and growth stage. The initial investment size typically ranges from $2 -$6 million. 
 
The firm is looking for new investments in the Healthcare IT and tech enabled healthcare services sectors. The firm focuses on healthcare companies targeting software, platform technology, solutions, data, and analytics. The fund is most interested in companies seeking to improve patient care and the provider experience, reduce healthcare costs, or make the healthcare industry more efficient in this rapidly changing marketplace. The firm has been active in HCIT companies developing eSource technology for use in clinical trials, clinical documentation intelligence, EHR system, and online source of research tools for global life science laboratories. 
 
The firm typically invests in private companies that have between $500K-$7M of annual revenue with a proven product and customer base. The firm typically looks to be a lead investor and usually requires a board or board observer seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A family office investment firm based in the US. The firm is actively seeking investment opportunities in the medtech space. Typical investment size is $250K, though the firm is capable of investing up to $1M. The firm invests anywhere from Seed to Series C rounds (growth/revenue-generating stage), and prefers to invest in USA-based companies. 
 
Within life sciences, the firm is primarily interested in medical devices. In particular, the firm is interested in surgical devices targeting areas including cancer, orthopedics, renal, cardiovascular, and neuro-related diseases as well as sepsis. The firm is open to companies in the earliest stages though they would like to see a working prototype in place prior to investment. The firm invests in all classes of medical devices including 510k and PMA. 
 
The firm has no specific company or management team requirements. The firm prefers to act as a co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A single-family evergreen fund headquartered in the US exclusively invests in medical devices; so far there are 15 portfolio companies from the U.S., Europe, and Israel, however the firm is open to investing global companies. The firm has two investment modalities: (1) investing in later-stage, commercial companies with typical check size being around $30M USD and (2) investing in early-stage companies with typical check size being around $10M USD. The earliest the firm will invest in is companies with clinical human data. The firm is active with the companies they invest in and will lead investments. 
 
The firm exclusively invests in medical device companies in a range of diseases states including, but not limited to, oncology, cardiovascular disease, and ophthalmology. The firm also invests in diagnostic devices. The firm is open to all classes of devices. Companies must show at least clinical human data. 
 
The firm will generally seek to take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A firm with offices in the US and Japan generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment. The firm invests 70% of its capital in the USA and Israel, with the remaining 30% in Japan. Under certain circumstances, the firm will invest outside those regions.  
 
The firm invests in advanced therapeutics, healthcare IT, novel (sensor based IoT) devices and diagnostics, and second generation tools and technologies in the biotech R&D/laboratory innovation field. The firm is open to any indication area, and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer. DEFTA Partners prefers to invest in technologies at an early stage of development. 
 
The firm is interested in working with high quality management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm headquartered in London invests in early-stage global health-tech companies from Pre-Seed to Series A rounds with flexible check sizes. RYSE has partnerships with key accelerators, global pharmaceuticals, and government organizations.  
 
The firm invests in digital health, diagnostics, and data applications such as CRMs and databases. The firm does not invest in therapeutics. The firm is generally indication-agnostic but has a preference in oncology. 
 
The firm will act as a lead and co-investor and typically takes board or observer seats. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.